Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Patients with B-cell lymphoma who were treated with CD19 CAR T-cells showed significant intestinal dysbiosis. This condition was marked by reduced bacterial diversity, decreased levels of soluble MAdCAM-1, and the absence of Akkermansia species, which was linked to resistance to the therapy. When Akkermansia massiliensis was administered orally, it led to an increased infiltration of CAR T-cells into the bone marrow, altered the CD4/CD8 CAR T-cell ratio, encouraged…